Patents by Inventor Nicolas Huot
Nicolas Huot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210010094Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18 mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.Type: ApplicationFiled: September 18, 2020Publication date: January 14, 2021Applicant: INSTITUT PASTEURInventors: Nicolas HUOT, Beatrice JACQUELIN, Michaela MULLER-TRUTWIN
-
Patent number: 10815540Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18 mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.Type: GrantFiled: March 27, 2019Date of Patent: October 27, 2020Assignee: INSTITUT PASTEURInventors: Nicolas Huot, Beatrice Jacquelin, Michaela Muller-Trutwin
-
Publication number: 20190218628Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.Type: ApplicationFiled: March 27, 2019Publication date: July 18, 2019Applicant: INSTITUT PASTEURInventors: Nicolas HUOT, Beatrice JACQUELIN, Michaela MULLER-TRUTWIN
-
Patent number: 10323289Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18 mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.Type: GrantFiled: June 25, 2018Date of Patent: June 18, 2019Assignee: INSTITUT PASTEURInventors: Nicolas Huot, Beatrice Jacquelin, Michaela Muller-Trutwin
-
Publication number: 20180371556Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18 mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.Type: ApplicationFiled: June 25, 2018Publication date: December 27, 2018Applicant: INSTITUT PASTEURInventors: Nicolas HUOT, Beatrice JACQUELIN, Michaela Muller-Trutwin
-
Patent number: 7925871Abstract: A data processing apparatus 2 is provided with one or more branch predictors 10 for generating branch predictions. A supervising predictor 12 is responsive to at least a stream of branch predictions to identify one or more cyclically recurring errors in the branch predictors and generate corrected behaviours for a prefetch unit 4.Type: GrantFiled: February 19, 2008Date of Patent: April 12, 2011Assignee: ARM LimitedInventors: Louis Marie Vincent Mouton, Nicolas Huot, Stephane Eric Sebastien Brochier, Gilles Eric Grandou
-
Publication number: 20090210685Abstract: A data processing apparatus 2 is provided with one or more branch predictors 10 for generating branch predictions. A supervising predictor 12 is responsive to at least a stream of branch predictions to identify one or more cyclically recurring errors in the branch predictors and generate corrected behaviours for a prefetch unit 4.Type: ApplicationFiled: February 19, 2008Publication date: August 20, 2009Applicant: ARM LimitedInventors: Louis-Marie Vincent Mouton, Nicolas Huot, Stephane Eric Sebastien Brochier, Gilles Eric Grandou
-
Publication number: 20080210673Abstract: The device comprises a laser-type coherent light radiation source transmitting ultrashort pulses, a dynamic beam shaping arrangement and an arrangement for using and processing a laser beam. The dynamic beam shaping arrangement comprises an optical system including a part for actively modifying the laser beam wavefront and a detecting part, excepting a phase meter, used for three-dimensionally shaping the beam. These parts are connected by a feed-back circuit and the active modifying part comprises a first fixed or active component and a second active component.Type: ApplicationFiled: April 19, 2006Publication date: September 4, 2008Applicants: IMPULSION, UNIVERSITE JEAN MONNET, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Eric Audouard, Nicolas Huot, Herve Soder
-
Patent number: 6674782Abstract: Laser type source of coherent luminous radiation including a resonant cavity, an amplification medium placed in the resonant cavity and a dynamic photosensitive material which is placed in the resonant cavity to form a self-adapting spectral and/or spatial filter, characterized in that the cavity is a ring laser cavity and in that the dynamic photosensitive material is placed at the intersection of two beams.Type: GrantFiled: April 25, 2001Date of Patent: January 6, 2004Assignee: Centre National de la Recherche Scientifique - CNRSInventors: GĂ©rald Roosen, Alain Brun, Nicolas Huot, Jean-Michel Jonathan, Gilles Pauliat, Patrick Georges
-
Publication number: 20020006150Abstract: Laser type source of coherent luminous radiation including a resonant cavity, an amplification medium placed in the resonant cavity and a dynamic photosensitive material which is placed in the resonant cavity to form a self-adapting spectral and/or spatial filter, characterized in that the cavity is a ring laser cavity and in that the dynamic photosensitive material is placed at the intersection of two beams.Type: ApplicationFiled: April 25, 2001Publication date: January 17, 2002Inventors: Gerald Roosen, Alain Brun, Nicolas Huot, Jean-Michel Jonathan, Gilles Pauliat, Patrick Georges